Study identifies risk factors for multiple melanoma skin cancer

October 04, 2005

Patients with a family history of multiple melanoma skin cancer are at increased risk of multiple primary melanomas, according to a study in the October 5 issue of JAMA.

In 2005, there will be an estimated 62,000 new cases of invasive melanoma and an estimated 7,600 deaths due to melanoma in the United States, according to background information in the article. Melanoma is the fifth leading cancer in men and the sixth leading cancer in women in the United States. The incidence of melanoma continues to rise at about 3 percent per year in the United States, with an estimated lifetime risk for an individual of 1.4 percent. This increasing incidence puts a larger portion of the population at risk not only for one primary melanoma but also for subsequent primary melanomas.

Cristina R. Ferrone, M.D., and colleagues from Memorial Sloan-Kettering Cancer Center, New York, conducted a study to identify the incidence and characteristics of patients at risk of developing multiple primary melanomas (MPM). The study included 4,484 patients diagnosed with a first primary melanoma between January 1, 1996, and December 31, 2002.

The researchers found that 385 patients (8.6 percent) had 2 or more primary melanomas, with an average of 2.3 melanomas per MPM patient. Seventy-eight percent had 2 primary melanomas. For 74 percent of patients, the initial melanoma was the thickest tumor. Fifty-nine percent presented with their second primary tumor within 1 year. Twenty-one percent of MPM patients had a positive family history of melanoma compared with only 12 percent of patients with a single primary melanoma (SPM). Thirty-eight percent of MPM patients had dysplastic nevi (DN; atypical moles) compared with 18 percent of SPM patients.

The estimated cumulative 5-year risk of a second primary tumor for the entire cohort was 11.4 percent, with almost half of that risk occurring within the first year. For patients with a positive family history or dysplastic nevi, the estimated 5-year risk of MPM was significantly higher at 19.1 percent and 23.7 percent, respectively. The most striking increase in incidence for the MPM population was seen for development of a third primary melanoma from the time of second primary melanoma, which was 15.6 percent at 1 year and 30.9 percent at 5 years.

"Patients with a positive family history or a history of DN are at significantly greater risk of developing MPM and should be enrolled in more intensive dermatologic surveillance programs. This high-risk subset of patients should also be further characterized genetically to further elucidate the biology and etiology of melanoma," the authors conclude.

(JAMA.2005; 294:1647-1654. Available pre-embargo to the media at www.jamamedia.org)
-end-


The JAMA Network Journals

Related Melanoma Articles from Brightsurf:

Boosting treatments for metastatic melanoma
University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life.

A promising new tool in the fight against melanoma
An Edith Cowan University (ECU) study has revealed that a key blood marker of cancer could be used to select the most effective treatment for melanoma.

New targets for melanoma treatment
A collaborative study led by Monash University's Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Innovative smartphone-camera adaptation images melanoma and non-melanoma
An article published in the Journal of Biomedical Optics (JBO), ''Point-of-care, multispectral, smartphone-based dermascopes for dermal lesion screening and erythema monitoring,'' shows that standard smartphone technology can be adapted to image skin lesions, providing a low-cost, accessible medical diagnostic tool for skin cancer.

Antihistamines may help patients with malignant melanoma
Can a very common allergy medicine improve survival among patients suffering from the serious skin cancer, malignant melanoma?

Blood test for deadly eye melanoma
A simple blood test could soon become the latest monitoring tool for the early detection of melanoma in the eye.

Analysis of melanoma in US by age groups
This study used registry data to determine annual rates of melanoma in pediatric, adolescent, young adult and adult age groups, and the findings suggest an apparent decrease among adolescent and young adults between 2006 and 2015 but increases in older adults.

Vitamin D dials down the aggression in melanoma cells
Vitamin D influences the behaviour of melanoma cells in the lab by making them less aggressive, Cancer Research UK scientists have found.

B cells linked to immunotherapy for melanoma
Immunotherapy uses our body's own immune system to fight cancer.

Five things to know about melanoma
'Five things to know about ... melanoma' in CMAJ (Canadian Medical Association Journal) provides a brief overview of this malignant skin cancer for physicians and patients.

Read More: Melanoma News and Melanoma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.